AZ304

AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM) . Anti-tumor activity[1].

Product Specifications

CAS Number

[942507-42-8]

Product Name Alternative

(2R,5S)-PF-06651600,PF-06651600 (malonate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Raf

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AZ304.html

Purity

99.77

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C)C(NC2=C3C=CC(OC)=CC3=NC=N2)=C1)C4=CC=CC(C(C)(C#N)C)=C4

Molecular Formula

C27H25N5O2

Molecular Weight

451.52

Precautions

H302, H315, H319, H335

References & Citations

[1]Ma R, et al. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. Br J Cancer. 2018 May;118 (11) :1453-1463.